Tatyana Levchenko

Tatyana Levchenko

Auto-generated profile, based on publicly available information

Tatyana Levchenko

Center for Pharmaceutical Biotechnology and Nanomedicine, 360 Huntington Avenue, 140 The Fenway, Northeastern University, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
MMMarwan Moussa
Marwan Moussa
SGS. Nahum Goldberg
S. Nahum Goldberg
GKGaurav Kumar
Gaurav Kumar
RSRupa R. Sawant
Rupa R. Sawant
TLTatyana Levchenko
Tatyana Levchenko
MAMuneeb Ahmed
Muneeb Ahmed

1 November 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
SMSamuel V. Mussi
Samuel V. Mussi
GPGaurav Parekh
Gaurav Parekh
PPPravin Pattekari
Pravin Pattekari
TLTatyana Levchenko
Tatyana Levchenko
YLYuri Lvov
Yuri Lvov
VTVladimir P. Torchilin
Vladimir P. Torchilin
A nanostructured lipid carrier (NLC) loaded with doxorubicin (DOX) has been shown to be cytotoxic against the human cancer cell lines A549 and MCF-7/Adr. In attempts to improve formulation characteristics, enhance pharmacokinetics and antitumor effects, we modified the surface of these NLC with an alternating layer-by-layer (LbL) assembly of polycation and polyanion polyelectrolytes and an additional coating with PEG using a simple method of core shell attachment. The formulation had a narrow size distribution, longer residence in the blood, lower accumulation in the liver, higher accumulation in tumors and a significant tumor growth inhibition effect. Thus, NLC-DOX nanopreparations complexes modified by LbL coating have the potential to enhance the anticancer effects of DOX against tumors.